PALO ALTO, Calif., March 02, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex”), an innovative revenue-generating company focused…
NON-REGULATORY PRESS RELEASE The NIPU trial is investigating the effect of adding UV1 vaccine to immunotherapy as second-line treatment of…
CHARLOTTESVILLE, Va., March 01, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical…
GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term,…
After years of successful collaboration, the esteemed organizations National Cancer Care Alliance (NCCA) and Quality Clinical Cancer Associates (QCCA) have…
GOTHENBURG, SE / ACCESSWIRE / February 29, 2024 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) The Lancet reports[1] that for the first…
Company continues progress across Ampligen® clinical development programs Growing body of promising data demonstrates Ampligen’s potential to address multiple high-value…
The SCI- 210 treatment is now available at clinical site for autism spectrum disorder clinical trial in pediatric patients, in…
Application based on Phase 3 DeFi trial in which nirogacestat significantly improved progression-free survival and objective response rate compared to…
Murine Study by the Wistar Institute Builds Upon Favorable Results Previously Reported by IMUNON With its Prototype PlaCCine Vaccine Modality…